Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Advanced Classical Hodgkin's Lymphoma
NCT02603419Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2016
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of avelumab in classical Hodgkin lymphoma (cHL) (6 arms), sponsored by Pfizer. Primary endpoints: Percent Target Occupancy (CD14+ Monocytes), Percent Target Occupancy (CD3+ T-Cells) and 8 more. Started Mar 2016; status: terminated.
02
Drugs
avelumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02603419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603419.